| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
23023 |
| Drug |
Mosunetuzumab |
| Brand |
Lunsumio® |
| Indication |
Mosunetuzumab (Lunsumio®) as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies. |
| Rapid review commissioned |
27/04/2023 |
| Rapid review completed |
25/05/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of mosunetuzumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
31/05/2023 |
| Pre-submission consultation with Applicant |
04/07/2023 |
| Full submission received from Applicant |
22/02/2024 |
| Preliminary review sent to Applicant |
22/10/2024 |
| NCPE assessment re-commenced |
18/11/2024 |
